Zabotti A, Aydin S, David P, Di Matteo A, McGonagle D
Nat Rev Rheumatol. 2025; .
PMID: 40075177
DOI: 10.1038/s41584-025-01229-6.
Christensen I, Lillegraven S, Sexton J, Kvien T, Uhlig T, Provan S
Rheumatol Adv Pract. 2025; 9(1):rkaf017.
PMID: 40061449
PMC: 11889454.
DOI: 10.1093/rap/rkaf017.
Cai Y, Zheng D, Chen X, Bai Z, Zhang J, Deng W
Commun Biol. 2025; 8(1):240.
PMID: 39953266
PMC: 11828935.
DOI: 10.1038/s42003-025-07698-5.
Lindgren L, Thomsen T, Hetland M, Aadahl M, Kristensen S, de Thurah A
Pilot Feasibility Stud. 2025; 11(1):15.
PMID: 39934926
PMC: 11817759.
DOI: 10.1186/s40814-025-01601-z.
Ebihara S, Owada Y, Ono M
Life Sci Alliance. 2025; 8(4).
PMID: 39919800
PMC: 11806258.
DOI: 10.26508/lsa.202403073.
Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study.
Serban T, Tramontano G, Pendolino M, Roccatello D, Epis O, Iannone F
Front Med (Lausanne). 2025; 11:1484988.
PMID: 39876867
PMC: 11773365.
DOI: 10.3389/fmed.2024.1484988.
Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound.
Cozzi G, Scagnellato L, Lorenzin M, Collesei A, Oliviero F, Damasco A
Front Med (Lausanne). 2025; 11():1482894.
PMID: 39764555
PMC: 11701151.
DOI: 10.3389/fmed.2024.1482894.
Rheumatology and Dermatology Multidisciplinary Clinic Improves Diagnostic Precision and Treatment Decisions in Patients Suspected or Diagnosed with Psoriatic Arthritis.
Matos C, Cunha-Santos F, Silva A, Alpalhao M, Filipe P, Fonseca J
J Multidiscip Healthc. 2025; 17:6143-6151.
PMID: 39741526
PMC: 11687110.
DOI: 10.2147/JMDH.S486029.
Psoriasis treatments in the stabilization of atherosclerosis: a systematic review.
Ji L, Ravi S, Wright L, Nguyen V, Wiley J, Vukelic M
Arch Dermatol Res. 2024; 317(1):159.
PMID: 39739136
PMC: 11685255.
DOI: 10.1007/s00403-024-03625-6.
The impact of psoriatic arthritis on quality of life: a systematic review.
James L, Hailey L, Suribhatla R, McGagh D, Amarnani R, Bundy C
Ther Adv Musculoskelet Dis. 2024; 16:1759720X241295920.
PMID: 39717741
PMC: 11664531.
DOI: 10.1177/1759720X241295920.
Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.
Ramsay H, Johnston R, Cyril S, Glennon V, Grobler L, Burgess D
Cochrane Database Syst Rev. 2024; 12():CD015880.
PMID: 39679815
PMC: 11648595.
DOI: 10.1002/14651858.CD015880.
Interdisciplinary approach to patients with psoriatic arthritis: a prospective, single-center cohort study.
Gross G, Lull C, von Ahnen J, Blauth M, Schwaan J, Olsavszky V
Ther Adv Chronic Dis. 2024; 15:20406223241293698.
PMID: 39619167
PMC: 11605746.
DOI: 10.1177/20406223241293698.
Skin and Nail Predictors of Psoriatic Arthritis Development: A Holistic Overview Integrating Epidemiological and Physiopathological Data.
Fratton Z, Giovannini I, Zabotti A, Errichetti E
J Clin Med. 2024; 13(22).
PMID: 39598023
PMC: 11594356.
DOI: 10.3390/jcm13226880.
The shared biomarkers and immune landscape in psoriatic arthritis and rheumatoid arthritis: Findings based on bioinformatics, machine learning and single-cell analysis.
Zhou K, Luo S, Wang Q, Fang S
PLoS One. 2024; 19(11):e0313344.
PMID: 39509434
PMC: 11542839.
DOI: 10.1371/journal.pone.0313344.
Regional variations in psoriatic arthritis: Insights from a nationwide multicenter analysis in Türkiye.
Kilic E, Kilic G, Tekeoglu I, Sargin B, Acer Kasman S, Alkan H
Arch Rheumatol. 2024; 39(3):339-349.
PMID: 39507837
PMC: 11537675.
DOI: 10.46497/ArchRheumatol.2024.10591.
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.
Siebert S, Schett G, Raychaudhuri S, Guma M, Chen W, Gao S
Ther Adv Musculoskelet Dis. 2024; 16:1759720X241283536.
PMID: 39493888
PMC: 11528637.
DOI: 10.1177/1759720X241283536.
Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis.
Kunzler T, Bamert M, Sprott H
Clin Rheumatol. 2024; 43(12):3723-3746.
PMID: 39467905
PMC: 11582271.
DOI: 10.1007/s10067-024-07193-y.
Comparative Ability of Various Immunosuppressants as Adjuvants on the Activity of T1D Vaccine.
Wang X, Xie M, Li T, Shi J, Wu M, Zhang S
Vaccines (Basel). 2024; 12(10).
PMID: 39460283
PMC: 11511529.
DOI: 10.3390/vaccines12101117.
Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies.
Menon S, Shoji S, Tsuchiwata S, Fallon L, Kanik K
J Clin Pharmacol. 2024; 65(3):369-377.
PMID: 39453735
PMC: 11867917.
DOI: 10.1002/jcph.6147.
Factors Associated with Treatment Satisfaction in Korean Patients with Psoriasis.
Jung S, Suh D, Lee S
Patient Prefer Adherence. 2024; 18:2093-2105.
PMID: 39385994
PMC: 11461761.
DOI: 10.2147/PPA.S485512.